Načítá se...
MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
Approximately 18% of ovarian cancers have an underlying genetic predisposition and many of the genetic alterations have become intervention and therapy targets. Although mutations in MutY homolog (MUTYH) are best known for MUTYH associated polyposis and colorectal cancer, it plays a role in the deve...
Uloženo v:
| Vydáno v: | Diagnostics (Basel) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7825630/ https://ncbi.nlm.nih.gov/pubmed/33419231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics11010084 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|